These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35274287)

  • 1. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Wei H; Zhou C; Liu B; Lin D; Li Y; Wei S; Gong B; Zhang G; Liu K; Gong X; Fang Q; Liu Y; Qiu S; Gu R; Song Z; Chen J; Yang M; Zhang J; Jin J; Wang Y; Mi Y; Wang J
    Br J Haematol; 2022 May; 197(4):442-451. PubMed ID: 35274287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
    Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
    [No Abstract]   [Full Text] [Related]  

  • 3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
    Wang B; Wen L; Wang Z; Chen S; Qiu H
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
    Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
    Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with
    Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
    Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
    Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
    [No Abstract]   [Full Text] [Related]  

  • 9. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
    Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
    Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
    Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
    Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
    Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
    Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of different genetic subtypes of CEBPA mutated AML.
    Fasan A; Haferlach C; Alpermann T; Jeromin S; Grossmann V; Eder C; Weissmann S; Dicker F; Kohlmann A; Schindela S; Kern W; Haferlach T; Schnittger S
    Leukemia; 2014 Apr; 28(4):794-803. PubMed ID: 24056881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical characteristics and prognosis of cytogenetically normal AML with single mutations of CEBPA.
    Kang Y; Chen X; Fang F; Zhang L; Wang J; Tian C; Guo W; Xu J; Ren H; Muyey DM; Tan Y; Xu Z; Wang H
    Int J Lab Hematol; 2021 Dec; 43(6):1424-1431. PubMed ID: 34216417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
    Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Teng W; Cao P; Nie D; Ma X; Wang T; Lu P; Liu H
    Cancer Gene Ther; 2020 Aug; 27(7-8):599-606. PubMed ID: 31477806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.
    Damm F; Wagner K; Görlich K; Morgan M; Thol F; Yun H; Delwel R; Valk PJM; Löwenberg B; Heuser M; Ganser A; Krauter J
    Br J Haematol; 2012 Jul; 158(2):208-215. PubMed ID: 22568493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Kanamori H; Usuki K; Uoshima N; Yanada M; Takeuchi J; Mizuno I; Kanda J; Okamura H; Yano S; Tashiro H; Shindo T; Chiba S; Tomiyama J; Inokuchi K; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):200-209. PubMed ID: 32495317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
    Heidrich K; Thiede C; Schäfer-Eckart K; Schmitz N; Aulitzky WE; Krämer A; Rösler W; Hänel M; Einsele H; Baldus CD; Trappe RU; Stölzel F; Middeke JM; Röllig C; Taube F; Kramer M; Serve H; Berdel WE; Ehninger G; Bornhäuser M; Schetelig J;
    Ann Oncol; 2017 Nov; 28(11):2793-2798. PubMed ID: 28945881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.